Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Characteristics and Outcomes of Acute Megakaryoblastic Leukemia With t(1;22)(p13;q13) in Children.

Pediatric blood & cancer·2026
Same author

Clinical and molecular characterization of thrombocytosis in transient abnormal myelopoiesis.

Leukemia·2026
Same author

Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders.

British journal of haematology·2026
Same author

Impact of Conditioning Regimen Type on Outcomes in Pediatric Patients with De Novo Advanced Myelodysplastic Syndrome Undergoing Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy·2025
Same author

Outcome of chemotherapy dose reduction in overweight Japanese children with acute lymphoblastic leukemia.

International journal of hematology·2025
Same author

Case report of neuronopathic mucopolysaccharidosis type II: Early intracerebroventricular enzyme replacement therapy and hematopoietic cell transplantation with developmental outcomes up to 5 years of age.

Molecular genetics and metabolism reports·2025

Related Experiment Video

Updated: Jul 10, 2026

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

[Inherited bone marrow failure syndromes].

Asahito Hama1

  • 1Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|July 8, 2026
PubMed
Summary

Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome impacting red blood cell production due to ribosome issues. Gene therapy shows promise for treating RPS19-deficient DBA by restoring normal hematopoiesis.

Keywords:
Diamond-Blackfan anemiaInherited bone marrow failure syndromedyserythropoiesisribosomal protein

More Related Videos

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Related Experiment Videos

Last Updated: Jul 10, 2026

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Diamond-Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by reduced reticulocytes and erythroid precursors.
  • DBA is primarily caused by heterozygous mutations in ribosomal protein genes, leading to ribosome dysfunction.
  • Impaired erythropoiesis in DBA involves p53 activation, translation defects, inflammation, and heme synthesis imbalance.

Purpose of the Study:

  • To summarize the pathophysiology of Diamond-Blackfan anemia.
  • To review current treatment strategies and their limitations.
  • To highlight recent advances in gene therapy for DBA.

Main Methods:

  • Literature review of DBA pathophysiology, clinical features, and treatment outcomes.
  • Analysis of studies on ribosomal protein gene mutations and their impact on erythropoiesis.
  • Evaluation of emerging gene therapy approaches for DBA.

Main Results:

  • DBA is linked to ribosome dysfunction and impaired red blood cell production.
  • Steroid therapy is a primary treatment, but many patients develop resistance.
  • Hematopoietic cell transplantation offers a curative option, and gene therapy shows promise.

Conclusions:

  • DBA pathogenesis involves complex molecular pathways affecting erythropoiesis.
  • Current treatments have limitations, necessitating alternative therapeutic strategies.
  • Lentiviral vector-mediated gene therapy presents a potential new avenue for treating DBA, particularly RPS19 deficiency.